SCHEMBL21223232

SCHEMBL21223232

Cc1ccc2c(n1)CCC2O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.41
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
POLL Q9UGP5 1/20 0.35
UGT2B17 O75795 2/20 0.33
PDK2 Q15119 1/20 0.33
PDK4 Q16654 1/20 0.33
HCRTR1 O43613 2/20 0.33
HCRTR2 O43614 2/20 0.33
HTT P42858 1/20 0.33
METAP2 P50579 1/20 0.32
RAB9A P51151 2/20 0.32
CCR1 P32246 2/20 0.32
CCR5 P51681 1/20 0.32
CYP2C19 P33261 1/20 0.32
AURKA O14965 1/20 0.32
DAPK3 O43293 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
CSF1R P07333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25693008 0.89 GRM5 (0.52) GRM5DRD2DRD1UGT2B17AURKA
SCHEMBL14931524 0.89 GRM5 (0.52) GRM5DRD2DRD1UGT2B17AURKA
SCHEMBL6845116 0.78 DRD2 (0.38) DRD2DRD1PDK2PDK4HCRTR1
SCHEMBL10238794 0.78 DRD2 (0.38) DRD2DRD1PDK2PDK4HCRTR1
SCHEMBL6845166 0.77 DRD2 (0.37) DRD2DRD1PDK2PDK4HCRTR1
SCHEMBL21223419 0.77 DRD2 (0.37) DRD2DRD1PDK2PDK4HCRTR1
SCHEMBL6845212 0.77 DRD2 (0.37) DRD2DRD1PDK2PDK4HCRTR1
SCHEMBL21223327 0.77 GRM5 (0.41) GRM5POLLAURKADAPK3PRKD3
SCHEMBL31183085 0.77 GRM5 (0.41) GRM5POLLAURKADAPK3PRKD3
SCHEMBL31137302 0.77 GRM5 (0.41) GRM5POLLAURKADAPK3PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213076-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-07-07 US disclosed
US-20220213076-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-07-07 US disclosed
US-11312709-B2 Ghrelin O-acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-04-26 US disclosed
US-11312709-B2 Ghrelin O-acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-04-26 US disclosed
US-20210053955-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-02-25 US disclosed
US-20210053955-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-02-25 US disclosed
EP-3749304-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-12-16 EP disclosed
WO-2019149959-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-08-08 WO disclosed
WO-2019149959-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213076-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS MBOAT4, GIPR, GPR119 GRM5 203/4885DRD2 864/4885DRD1 1254/4885
US-11312709-B2 Ghrelin O-acyltransferase inhibitors MBOAT4, GIPR, GPR119 GRM5 203/4885DRD2 864/4885DRD1 1254/4885
US-20210053955-A1 GHRELIN O-ACYLTRANSFERASE INHIBITORS MBOAT4, GIPR, GPR119 GRM5 203/4885DRD2 864/4885DRD1 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.